IP & Biotech
CureVac sues Moderna over COVID-19 vaccine patents
What's happening
German biotech CureVac filed a lawsuit against Moderna in Delaware federal court on Friday, April 24, 2026, alleging that Moderna's COVID-19 vaccine, Spikevax, infringed on eight U.S. patents related to mRNA stabilization technology.
This legal action follows BioNTech's acquisition of CureVac last year, positioning the combined entity as a major litigator against Moderna in the race to secure royalties from the multi-billion dollar mRNA vaccine market.
What's changing / Business impact
-
Intensifies legal battles in: mRNA technology and foundational vaccine IP ownership.
-
Potential financial implications: CureVac is seeking significant damages and royalties from Moderna's historical and ongoing Spikevax sales.
-
Could influence future mRNA innovation access: Decisions on platform-wide patents may dictate how other companies license mRNA tech for oncology and rare diseases.
Why this matters
Innovation in healthcare is not just about discovery, it's also about ownership of technology.
This shows:
-
Intellectual property remains the core competitive moat for the next decade of genomic medicine.
-
Legal outcomes can reshape: pricing, global access, and cross-pharma partnerships.
-
Future innovation depends on who controls foundational tech; a win for CureVac could force an industry-wide re-evaluation of mRNA licensing models.